Pulmonary Complications Secondary to Immune Checkpoint Inhibitors

Table 2

Baseline characteristics of the 10 patients with pneumonitis secondary to ICI use.

Baseline characteristics	Patients, no. (%)
Age (y)
≥65	4 (40)
<65	6 (60)
Male sex	7 (70)
Body mass index >30	6 (60)
Positive smoking history (current and prior use)	7 (70)
Cancer stage IV at time of pulmonary complications	10 (100)
Site of metastasis
Liver	4 (40)
Bone	6 (60)
Charlson comorbidity index
0-8	4 (40)
9-17	6 (60)
Previous radiation history	8 (80)
Chemotherapy before initiation of ICI use
Yes	7 (70)
No	3 (30)
Medical history of COPD or emphysema
Yes	2 (20)
No	8 (80)
Use of corticosteroid inhaler at time of pneumonitis
Yes	1 (0)
No	9 (90)

Abbreviations: COPD: chronic obstructive pulmonary disease; ICI: immune checkpoint inhibitor.